Skip to main content
Erschienen in: Annals of Nuclear Medicine 6/2009

01.08.2009 | Case Report

Simultaneous FDG PET+/Glut1+ lung and FDG PET−/Glut1− subcarinal lymph node metastases from prostate cancer

verfasst von: Amir H. Khandani, William K. Funkhouser, Richard Feins, Mark A. Socinski

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

A 78-year-old man with a history of prostate cancer and a rise in PSA presented with a new left lung mass, detected on computed tomography (CT). Positron emission tomography (PET)–CT (PET–CT) scan with 18-F fluorodeoxyglucose glucose revealed intense uptake in the lung mass without any other areas of abnormal uptake. Surgical resection of the mass and mediastinal lymph node dissection revealed metastatic adenocarcinoma from prostate cancer in the left lung mass (tumor size 5 cm) as well as in a subcarinal lymph node (tumor size 1.9 cm), which were identical on hematoxylin and eosin stains with a Gleason score of 8. The size of the subcarinal lymph node metastasis could not explain its non-visualization on PET. Glut1 stains of the lung mass were positive with moderate (2+ out of maximum 3+) reactivity in 95% of the carcinoma cells, whereas Glut1 stains of the subcarinal lymph node were negative with faint (1+ out of maximum 3+) reactivity in ca. 30% of the carcinoma cells. The low Glut1 expression in the subcarinal lymph node is the most likely explanation for its non-visualization on PET.
Literatur
1.
Zurück zum Zitat Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008;10:890–5.PubMedCrossRef Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008;10:890–5.PubMedCrossRef
2.
Zurück zum Zitat Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, Maldonado A, García de Barajas S, Calero-García R, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23:8348–56.PubMedCrossRef Pozo-Rodríguez F, Martín de Nicolás JL, Sánchez-Nistal MA, Maldonado A, García de Barajas S, Calero-García R, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol. 2005;23:8348–56.PubMedCrossRef
3.
Zurück zum Zitat Warburg O, Posener K, Negelein E. The metabolism of the carcinoma cell. In: The metabolism of tumors. New York: Richard R. Smith Inc;1931:129–69. Warburg O, Posener K, Negelein E. The metabolism of the carcinoma cell. In: The metabolism of tumors. New York: Richard R. Smith Inc;1931:129–69.
4.
Zurück zum Zitat Rogers S, Docherty SE, Slavin JL, Henderson MA, Best JD. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 2003;193:225–33.PubMedCrossRef Rogers S, Docherty SE, Slavin JL, Henderson MA, Best JD. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 2003;193:225–33.PubMedCrossRef
5.
Zurück zum Zitat Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol. 1998;25:593–7.PubMedCrossRef Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol. 1998;25:593–7.PubMedCrossRef
6.
Zurück zum Zitat Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with 18-F FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–85.PubMedCrossRef Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with 18-F FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–85.PubMedCrossRef
7.
Zurück zum Zitat de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55:79–87.PubMedCrossRef de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55:79–87.PubMedCrossRef
8.
Zurück zum Zitat Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.PubMedCrossRef Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.PubMedCrossRef
9.
Zurück zum Zitat Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035–42.PubMedCrossRef Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035–42.PubMedCrossRef
10.
Zurück zum Zitat Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057–63.PubMed Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057–63.PubMed
11.
Zurück zum Zitat Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623–9.PubMedCrossRef Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623–9.PubMedCrossRef
12.
Zurück zum Zitat Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med. 2003;17:327–31.PubMedCrossRef Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med. 2003;17:327–31.PubMedCrossRef
13.
Zurück zum Zitat Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;90:1238–43.PubMed Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;90:1238–43.PubMed
Metadaten
Titel
Simultaneous FDG PET+/Glut1+ lung and FDG PET−/Glut1− subcarinal lymph node metastases from prostate cancer
verfasst von
Amir H. Khandani
William K. Funkhouser
Richard Feins
Mark A. Socinski
Publikationsdatum
01.08.2009
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2009
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0264-2

Weitere Artikel der Ausgabe 6/2009

Annals of Nuclear Medicine 6/2009 Zur Ausgabe